Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Spectral AI submitted its DeepView diagnostic to the FDA and filed Form 10-Q with the Securities and Exchange Commission (Bangladesh).

2 reports, 2 independent Updated Aug 14
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Spectral AI submitted its DeepView diagnostic to the FDA and filed Form 10-Q with the Securities and Exchange Commission (Bangladesh).

Who's involved

What this event is mainly about
FDASecurities and Exchange Commission (Bangladesh)

How it developed

Newest first. Tap a step to see who reported it.
  1. Spectral AI submitted a De Novo application to the FDA and announced financial results from Dallas.Sub-event
  2. Spectral AI submitted its DeepView diagnostic to the FDA and filed a Form 10-Q with the SEC.1 source

Keep exploring

Part of

A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Also in this story

All 83 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Zacks Small Cap ResearchMDAI: Second Quarter Results By John Vandermosten, CFA NASDAQ:MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ:MDAI) reports second quarter earnings just weeks after announcing the D
  • GuruFocus.comSpectral AI Inc (MDAI) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full